RET and sarcoma: Furthermore, despite the fact that there are breakthroughs in utilizing FDA-approved larotrectinib [3] and entrectinib [4] in NTRK gene fusion-positive sarcomas and selpercatinib in RET gene fusion-positive sarcomas [5], a significant step towards individualized precision medicine, compared with a large pool of sarcomas harboring fusions, more progress is being expected.